Harrow Health/HROW

$10.54

-2.86%
-
1D1W1MYTD1YMAX

About Harrow Health

Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.

Ticker

HROW

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Mark Baum

Employees

315

Headquarters

Nashville, United States

Harrow Health Metrics

BasicAdvanced
$417.99M
Market cap
-
P/E ratio
-$0.74
EPS
0.53
Beta
-
Dividend rate
$417.99M
0.53494
$28.25
$7.60
433.26K
2.827
2.607
258.842
258.842
0.04%
-10.4%
-49.64%
-12.14%
3.211
5.874
46.95%
-44.15%
38.63%

What the Analysts think about Harrow Health

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 4 analysts.
143.36% upside
High $32.60
Low $20.00
$10.54
Current price
$25.65
Average price target

Harrow Health Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-25.06% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$36.3M
6.14%
Net income
$-9.1M
111.63%
Profit margin
-25.06%
99.36%

Harrow Health Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 459.7%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.22
-$0.14
-$0.13
-$0.25
-
Expected
-$0.05
-$0.04
$0.04
-$0.04
-$0.20
Surprise
312.5%
250%
-467.93%
459.7%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Harrow Health stock?

Harrow Health (HROW) has a market cap of $383.68M as of April 20, 2024.

What is the P/E ratio for Harrow Health stock?

The price to earnings (P/E) ratio for Harrow Health (HROW) stock is 0 as of April 20, 2024.

Does Harrow Health stock pay dividends?

No, Harrow Health (HROW) stock does not pay dividends to its shareholders as of April 20, 2024.

When is the next Harrow Health dividend payment date?

Harrow Health (HROW) stock does not pay dividends to its shareholders.

What is the beta indicator for Harrow Health?

Harrow Health (HROW) has a beta rating of 0.56. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Harrow Health stock price target?

The target price for Harrow Health (HROW) stock is $25.65, which is 145.45% above the current price of $10.45. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Harrow Health stock

Buy or sell Harrow Health stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing